Pharma Commercialization
The pharma commercialization sector operates within Houlihan Lokey’s Business Services Group, which has earned a reputation for providing superior service and achieving outstanding results in M&A advisory, capital-raising, restructuring, and financial and valuation advisory services.
Our clients run the gamut from early-stage businesses and midsized companies to large, publicly traded corporations. We understand that an industry driven by innovation and change requires the sophistication of an advisor who can think ahead of the market and utilize solid industry relationships to help advance your vision. We optimize client outcomes by running executed, competitive processes, by focusing on deep domain knowledge to position for synergy and scarcity value, and by leveraging our world-class strategic and private equity access to bring the right senior decision-makers to the negotiation table.
| Advisor | Deals |
|---|---|
| Houlihan Lokey | 63 |
| Rothschild | 46 |
| Lincoln International | 32 |
| Clearwater International | 31 |
| Goldman Sachs | 27 |
Subsectors
How We Can Help
Our firm is extremely well equipped to help our clients navigate uncertainty and capitalize on opportunity. We respond quickly to challenging situations and are constantly helping clients analyze, structure, negotiate, and execute the best possible solutions from both strategic and financial perspectives.
Corporate Finance
- Mergers and Acquisitions
- Capital Markets
- Private Funds Advisory
- Board Advisory Services
Financial Restructuring
- Company Advisory
- Creditor Advisory
Financial and Valuation Advisory
- Portfolio Valuation and Fund Advisory
- Transaction Opinions
- Corporate Valuation Advisory Services
- Transaction Advisory Services
- Real Estate Valuation and Advisory
- Dispute Resolution Consulting
Contact Us
Selected Transactions
Houlihan Lokey is pleased to announce that OPEN Health, a leading global provider of scientific communications and market access services to the pharmaceutical industry, a portfolio company of Amulet Capital Partners, LP (Amulet), has been acquired by Astorg. The transaction closed on July 13, 2022.
Established in 2011 and headquartered in London, OPEN Health is a key partner to its customers in helping them develop strategies for evidence generation and data communication by leveraging their extensive scientific knowledge and relentless focus on quality. Together, this approach consistently delivers best-in-class scientific communications, HEOR, and market access services to an ever-increasing audience.
OPEN Health has more than 1,000 employees in 15 locations and six countries, across North America, Europe, and Asia. OPEN Health serves over 170 life sciences customers, including 48 of the top 50 pharmaceutical companies. OPEN Health’s existing management team, led by CEO Rob Barker, will continue to lead the organization, building on a strong track record of organic growth and strategic acquisitions.
Astorg is a European private equity firm with over €17 billion of assets under management. Astorg works with entrepreneurs and management teams to acquire market-leading global companies headquartered in Europe or the U.S., providing them with the strategic guidance, governance, and capital they need to achieve their growth plans.
Amulet is a middle-market private equity investment firm based in Greenwich, Connecticut, focused exclusively on the healthcare sector. Amulet seeks to achieve long-term capital appreciation through privately negotiated investments in companies.
Houlihan Lokey served as exclusive financial advisor to OPEN Health and Amulet. This deal highlights Houlihan Lokey’s leading experience in the pharma services space and represents the firm’s 14th transaction in this sector since 2019.
